CD19 and cancer: To determine how IDRs affect the cytotoxicity of CAR-Ts against cancer cells, we cocultured the control or IDR CAR-Ts (Fig. 2a) with modified Nalm6, a B cell leukemia line that expresses either high or low CD19 (Fig. 2b).